Biohaven (BHVN) Ltd. announced that it has commenced an underwritten public offering of $150M of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. J.P. Morgan and Goldman Sachs & Co. are acting as the book-running managers of the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Strategic Pipeline Focus and Cost Management Drive Buy Rating for Biohaven Ltd.
- Biohaven reports Q3 EPS ($1.64), consensus ($1.61)
- Biohaven price target lowered to $30 from $75 at Piper Sandler
- Biohaven price target lowered to $16 from $33 at BTIG
- Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes